New England Journal of Medicine Publishes Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis BronchiectasisPRNewsWire • 09/07/20
Insmed Incorporated (INSM) CEO William Lewis on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/08/20
Insmed Reports Second Quarter 2020 Financial Results and Provides Business UpdatePRNewsWire • 08/06/20
Insmed to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 6, 2020PRNewsWire • 07/27/20
Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment OptionsPRNewsWire • 07/24/20
New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung DiseasePRNewsWire • 07/07/20
Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at ATS Virtual Clinical Trials SessionPRNewsWire • 06/24/20
Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)PRNewsWire • 06/08/20
Insmed Incorporated (INSM) CEO Will Lewis on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 04/30/20
Insmed, Incorporated (INSM) CEO Will Lewis on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/25/20
Insmed's stock soars after trial of bronchiectasis treatment achieves key endpointsMarket Watch • 02/03/20
Insmed, Inc. (INSM) CEO Will Lewis on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 10/30/19
Insmed, Inc. (INSM) CEO Will Lewis on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/03/19